BioStem Technologies Reports Third Quarter 2025 Financial Results
POMPANO BEACH, FL, November 13, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the third quarter ended September 30, 2025.
Recent Business Highlights
· Sold approximately 35,000 square centimeters of placental allografts, representing 40% quarter-over-quarter product volume growth
· Reported positive top-line randomized controlled trial clinical results demonstrating superior outcomes with BioREtain® Allografts in diabetic foot ulcers as published in the International Journal of Tissue Repair and submitted to CMS for consideration for inclusion as a covered product ahead of the November 1, 2025 deadline
· Continued enrollment of subjects the BioREtain venous leg ulcer randomized controlled trial ahead of schedule, supporting progress toward top line read out in Q1 2026
· Received positive coverage decisions from Medi-Cal and Texas Medicaid, the regions covered by these two payers covers more than 90 million Americans and represents an $800 million to $1 billion annual opportunity for skin substitutes across diabetic-foot and venous-leg ulcers
· Established a partnership with a Service-Disabled Veteran-Owned Small Business (SDVOSB) to serve the Department of Veterans Affairs (VA) through the launch of our American Amnion product in Q4.
· Secured land purchase at the research park at Florida Atlantic University in Boca Raton for future headquarters
· FDA closed out our prior inspection from 2023 and the associated Form 483. The FDA conducted a new 361 inspection, which was completed with no comments or observations—a completely clean inspection.
· Appointed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm
To read the complete release, please click here.
Contact BioStem Technologies, Inc.
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Phone: 954-380-8342
Investor Relations: Philip Trip Taylor, Gilmartin Group ir@biostemtech.com